EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Applications and Complementarity of Organ‐Chips and Animal Models in Lung Cancer Driver Gene Research

Lu-Kai Wang iD, Tsai-Jung Wu iD, Fu-Ming Tsai iD

Cell Biology International · 2026

DOI: 10.1002/cbin.70108 ↗

At a glance

Übersichtsarbeit in Cell Biology International, 2026. Written by Lu-Kai Wang and 2 co-authors. Institution: National Center for Biomodels, National Institutes of Applied Research, Taipei, Taiwan. Major MEDLINE topics: Lung Neoplasms. Cited 1 times so far (Crossref); 97 references. Funded by: This study was supported by Taipei Tzu Chi Hospital through the Buddhist Tzu Chi Medical Foundation [TCRD-TPE-113-20]..

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Alterations in driver genes in lung cancer, such as those in EGFR , KRAS , EML4‐ALK , and TP53 , play pivotal roles in tumor progression, therapeutic response, and resistance development. Therefore, it is important to develop research models that reflect both human tumor characteristics and systemic physiological responses. This review summarizes and compares previous studies of the application and complementarity of organ‐chip technologies (including organoids and lung‐on‐a‐chip) and traditional animal models (genetically engineered mouse models and patient‐derived xenografts) for investigating the same genetic alterations. Existing literature demonstrates that animal models are well‐suited for studying long‐term tumor evolution and metastasis because of their intact immune systems, physiological environments, and immune‐based therapies. However, organ‐chips can rapidly establish models in controllable microenvironments, enabling the high‐throughput screening of drugs and analyses of resistance mechanisms. Although both approaches demonstrate consistent trends in oncogenic potential and drug sensitivity across multiple genetic alterations, they differ in terms of time efficiency, microenvironmental control, and the capacity to recapitulate systemic responses. Thus, the two platforms may be complementary in preclinical lung cancer research, and their combined application may enhance the accuracy of gene function validation, drug efficacy evaluation, and clinical translation.

Subjects

MeSH terms (MEDLINE)

Lung NeoplasmsAnimalsHumansDisease Models, AnimalMiceOrganoidsTumor MicroenvironmentLab-On-A-Chip Devices

Author keywords

EGFR L858R/T790MEML4‐ALKGenetically engineered mouse modelsKRAS G12D/G12CLung cancerOrgan‐on‐a‐chip

Authors and institutions

  • National Center for Biomodels, National Institutes of Applied Research, Taipei, Taiwan.
  • Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
  • Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.

ORCID profiles: Lu-Kai Wang, Tsai-Jung Wu, Fu-Ming Tsai

Funding

  • This study was supported by Taipei Tzu Chi Hospital through the Buddhist Tzu Chi Medical Foundation [TCRD-TPE-113-20].

Cite

APA

Wang, L. K., Wu, T. J., & Tsai, F. M. (2026). Applications and Complementarity of Organ‐Chips and Animal Models in Lung Cancer Driver Gene Research. Cell Biology International. https://doi.org/10.1002/cbin.70108

Vancouver

Wang LK, Wu TJ, Tsai FM. Applications and Complementarity of Organ‐Chips and Animal Models in Lung Cancer Driver Gene Research. Cell Biology International. 2026. doi:10.1002/cbin.70108

BibTeX
@article{Wang2026,
  author = {Wang, Lu-Kai and Wu, Tsai-Jung and Tsai, Fu-Ming},
  title = {Applications and Complementarity of Organ‐Chips and Animal Models in Lung Cancer Driver Gene Research},
  journal = {Cell Biology International},
  year = {2026},
  doi = {10.1002/cbin.70108}
}
Start for free →